Look back at pharma news in week to January 11

13 January 2019

By Barbara Obstoj-Cardwell. Editor

There was further clear evidence of major M&A activity in the start of the New Year, with Eli Lilly announcing it has agreed an $8 billion deal to acquire Loxo Oncology, following swiftly on the previous week’s $74 billion deal from Bristol-Myers to buy biotech Celgene. On the research front, Axsome impressed with mid-stage results for its major depressive disorder drug AXS-05. And among deal-making, Gilead Sciences entered into another NASH collaboration, this one with South Korea’s Yuhan Corp.

Lilly to acquire Loxo sparking targeted oncology M&A resurgence

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK